DDInter6 DDInter1729
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Epoprostenol {u} (Compound) causes {v} (Side Effect) Hyperhidrosis
Hyperhidrosis {u} (Side Effect) is caused by {v} (Compound) Sulindac
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolmetin
Tolmetin {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Sulindac
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolmetin
Tolmetin {u} (Compound) palliates {v} (Disease) osteoarthritis
osteoarthritis {u} (Disease) is palliated by {v} (Compound) Sulindac
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolmetin
Tolmetin {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Sulindac
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PPARD
PPARD {u} (Gene) is bound by {v} (Compound) Sulindac
Abciximab {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Clopidogrel {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Sulindac
Abciximab {u} may lead to a major life threatening interaction when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Sulindac
Abciximab {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Clopidogrel {u} (Compound) causes {v} (Side Effect) Body temperature increased
Body temperature increased {u} (Side Effect) is caused by {v} (Compound) Sulindac
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Sulindac (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Sulindac (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Sulindac (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Sulindac (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) binds PPARD (Gene) and Treprostinil (Compound) upregulates PPARD (Gene) and PPARD (Gene) is bound by Sulindac (Compound)
Abciximab may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Sulindac (Compound)
Abciximab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Sulindac (Compound)
Abciximab may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Sulindac (Compound)